BLADDER CANCER THERAPEUTICS MARKET ANALYSIS

Bladder Cancer Therapeutics MarketSize and Trends

Bladder cancer therapeutics market taxonomy:

Global Market by Bladder Cancer Type

• Urothelial Carcinoma
• Squamous Cell Carcinoma
• Adenocarcinoma

Global Market by Treatment Type

• Surgery
• Transurethral bladder tumor resection (TURBT)
• Cystectomy
• Urinary Diversion
• Chemotherapy
• Intravesical (local) Chemotherapy
• Systemic (whole body) Chemotherapy
• Immunotherapy
• Intravesical Therapy
• Interferon Therapy
• Radiation Therapy

Global Market by Test Type

• Biopsy
• Cystoscopy
• Urine Cytology
• Urinalysis
• Bladder Ultrasound

Global Market by Gender

• Men
• Women

Global Market by Geography

• North America
• Europe
• APAC
• Latin America
• Middle East
• Africa

Market- Trends

Increasing incidence rate, especially in developed regions fueling growth of bladder cancer therapeutics market

As per stats released by the International Agency for Research on Cancer (IARC), 59% of bladder cancer cases are observed in developed countries, with Belgium reporting the highest number of bladder cancer cases.

As per stats released by Cancer Research UK—a charity involved in cancer research and development—here were around 10,100 new cases reported in the U.K. in 2014. Bladder cancer accounts for around 3% of all new cancer cases reported in the U.K. As per a study by the American Society of Clinical Oncology (ASCO), incidence rate of the disease has decreased by around 12% in the U.K. in the recent past.

According a study by Cancer Research Institute, bladder cancer is more prevalent among men than women. Around 77,000 new cases were diagnosed in the U.S. in 2016, leading to 16,000 deaths. Continuous advancements in clinical research resulted into increased survival rate of people suffering from bladder cancer, which is around 77% observed in last few years. As per the stats of American Cancer Society, bladder cancer accounts for 5% of all new cancer cases in the U.S.

Some are the major reasons behind bladder cancer are unhealthy habits. Smoking is a major cause along with that continuous exposure of industrial chemicals, drinking water with high level of arsenic, family history of bladder cancer, and long-term use of urinary catheters are the other causes of bladder cancer. In Africa and Middle East schistosomiasis and infested water are the leading cause of bladder cancer.

North America holds major share in the global bladder cancer therapeutics market, followed by Europe due to advanced treatments, developed economy, and easy access to advanced healthcare facilities. The market in APAC region will witness high growth rate in the near future, due to increasing per capita income, developing economy, government initiatives on improving healthcare infrastructure, growing FDI in healthcare, and rapidly increasing aging population. As per stats released by the Department of Industrial Policy and Promotion (DIPP), the healthcare sector in India witness FDI worth US$ 4.09 billion between April 2000 and September 2016. Also, medical tourism in the region is a flourishing business, due to easy access to high-quality low-cost treatment option. According to data released by the India Brand Equity Foundation (IBEF)— a Trust established by the Department of Commerce, Ministry of Commerce and Industry, Government of India—the medical tourism industry in India rakes in US$ 3 billion each year. This creates a highly conducive environment for growth of the bladder cancer therapeutics market in the region.